Jazz Pharmaceuticals PLC

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 4514.81, 4829.19, 5260.86, 5679, 5945.55 ], "ebit_estimate": [ 2062.11, 2105.26, 2401.61, 2614.81, 2667.95 ], "ebitda_estimate": [ 2288.04, 2407.87, 2477.93, 2657, 2659.45 ], "net_income_estimate": [ 1689.13, 1737.07, 1984.99, 2226.08, 2365.51 ], "per_share_eps_estimate": [ 13.26, 14.47, 19.79, 21.96, 26.36 ], "eps_nri_estimate": [ 25.28, 25.75, 29.04, 31.97, 34.14 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 84.99, 106.85, 129.44, 157.22, 185.32 ], "pretax_income_estimate": [ 1898.01, 1940.47, 2124.5, 2492.37, 2560.45 ], "operating_cash_flow_per_share_estimate": [ 23.45, 26.09, 33.83, 37.72, 39.91 ], "roa_estimate": [ 7.88, 9, 9.57, 8.05, 8.15 ], "roe_estimate": [ 25.29, 23.55, 22.22, 14.85, 14.05 ], "gross_margin_estimate": [ 89.92, 89.26, 88.71, 86.58, 85.25 ], "operating_cash_flow_estimate": [ 1549.88, 1724.71, 2236.38, 2493.29, 2638.05 ], "pettm_estimate": [ 18.38, 16.85, 12.32, 11.1, 9.25 ], "long_term_growth_rate_mean": 45.46, "long_term_revenue_growth_rate_mean": "7.20", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 45.46, "future_revenue_estimate_growth": 7.2, "future_ebit_estimate_growth": 45.44, "future_ebitda_estimate_growth": 44.7, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 49.71, "future_pretax_income_estimate_growth": 55.04, "future_book_value_per_share_estimate_growth": 22.88, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 18.24, "future_gross_margin_estimate_growth": -1.03, "future_operating_cash_flow_per_share_estimate_growth": 14.65 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 1111.97, 1153.26, 1185.95, 1110.07, 1180.67, 1259.9, 1315.5 ], "ebit_estimate": [ 516.58, 530.71, 522.63, 437.1, 545.4, 599.8, 626.1 ], "ebitda_estimate": [ 526.84, 546.11, 491.83, null, null, null, null ], "net_income_estimate": [ 413.26, 424.6, 420.01, 345.58, 452.97, 486.28, 506.81 ], "per_share_eps_estimate": [ 2.9, 3.33, 2.55, 3.2, 3.46, 3.78, 4 ], "eps_nri_estimate": [ 6.18, 6.36, 6.38, 5.65, 6.26, 6.85, 7.07 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 72.94, 76.23, 81.69, null, null, null, null ], "pretax_income_estimate": [ 474.77, 487.42, 480.34, 401.1, 514.4, 568.8, 600.1 ], "operating_cash_flow_per_share_estimate": [ 13.33, 15.72, 17.67, null, null, null, null ], "roa_estimate": [ 4, 2.6, 2.4, null, null, null, null ], "roe_estimate": [ 24, 21.43, 18.62, null, null, null, null ], "gross_margin_estimate": [ 90.31, 90.37, 89.99, 90.5, 89.75, 89.65, 89.55 ], "operating_cash_flow_estimate": [ 880.78, 1038.76, 1167.66, null, null, null, null ], "pettm_estimate": [ 20.36, 19.46, 18.77, 16.88, null, null, null ], "long_term_growth_rate_mean": 45.46, "long_term_revenue_growth_rate_mean": "7.20", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": 45.46, "future_revenue_estimate_growth": 7.2, "future_ebit_estimate_growth": 45.44, "future_ebitda_estimate_growth": 44.7, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 49.71, "future_pretax_income_estimate_growth": 55.04, "future_book_value_per_share_estimate_growth": 22.88, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 18.24, "future_gross_margin_estimate_growth": -1.03, "future_operating_cash_flow_per_share_estimate_growth": 14.65 }